The goal of this clinical intervention is to test if two forms of transcranial current stimulation, transcranial direct current stimulation (tDCS) or transcranial alternating current stimulation (tACS) can alleviate neuropathic eye pain in a sample of 20 patients. The main aims are: * Test if tDCS/tACS can alleviate neuropathic eye pain and/or other cerebral symptoms: brain fatigue, migraine, light sensitivity, etc. * Test if one stimulation method is superior to the other Patients will be treated for a total of fifteen 30-minute stimulation sessions, three times a day over a five-day period, each stimulation separated by approximately 4 hours, with either active tACS or tDCS over the scalp corresponding to primary sensory and motor areas. The patients will have questionnaires to monitor subjective experiences and pupillometry before and after treatment to monitor experimental outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from baseline subjective pain via neuropathic pain symptom inventory for the eye (NPSI-eye) at 1 week
Timeframe: through treatment completion, 1 week
Change from baseline subjective pain via neuropathic pain symptom inventory for the eye (NPSI-eye) at 2 weeks
Timeframe: through treatment completion, 2 weeks
Change from baseline subjective pain via neuropathic pain symptom inventory for the eye (NPSI-eye) at 1 month
Timeframe: through treatment completion, 1 month
Change from baseline subjective pain effect experiences via Defense and Veteran Pain Rating Scale (DVPRS) at 1 week
Timeframe: through treatment completion, 1 week
Change from baseline subjective pain effect experiences via Defense and Veteran Pain Rating Scale (DVPRS) at 2 weeks
Timeframe: through treatment completion, 2 weeks
Change from baseline subjective pain effect experiences via Defense and Veteran Pain Rating Scale (DVPRS) at 1 month
Timeframe: through treatment completion, 1 month
Change from baseline subjective mental symptoms via Mental Fatigue Scale (MFS) at 1 week
Timeframe: through treatment completion, 1 week
Change from baseline subjective mental symptoms via Mental Fatigue Scale (MFS) at 2 weeks
Timeframe: through treatment completion, 2 weeks
Change from baseline subjective mental symptoms via Mental Fatigue Scale (MFS) at 1 month
Timeframe: through treatment completion, 1 month
Change from baseline subjective ocular symptoms and symptom frequency via custom ocular pain questionnaire at 1 week
Timeframe: through treatment completion, 1 week
Change from baseline subjective ocular symptoms and symptom frequency via custom ocular pain questionnaire at 2 weeks
Timeframe: through treatment completion, 1 month
Change from baseline subjective ocular symptoms and symptom frequency via custom ocular pain questionnaire at 1 month
Timeframe: through treatment completion, 1 month
Number of patients with treatment-related adverse events as assessed by ocular pain questionnaire
Timeframe: through treatment completion, 1 month
Change from baseline pupil diameter in millimeters at 1 week
Timeframe: through treament completion, 1 week
Change from baseline pupil velocity in millimeters per second at 1 week
Timeframe: through treament completion, 1 week
Change from baseline pupil latency in milliseconds at 1 week
Timeframe: through treament completion, 1 week